Internal Reference Number: FOI_7296
Date Request Received: 11/07/2023 00:00:00
Date Request Replied To: 02/08/2023 00:00:00
This response was sent via: By Email
Request Summary: Oesophageal and Gastric Cancer
Request Category: Companies
| Question Number 1: How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: • CAPOX (Capecitabine with Oxaliplatin) <5 • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 0 • Lonsurf (Trifluridine - tipiracil) 0 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 • Any other systemic anti-cancer therapy <5 • Palliative care only unable to answer | |
| Question Number 2: How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with: • Nivolumab monotherapy or combination with Ipilimumab • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 2: • Nivolumab monotherapy or combination with Ipilimumab 1 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) <5 • Any other systemic anti-cancer therapy <5 • Palliative care only unable to answer | |
| Question Number 3: How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with: • Nivolumab monotherapy or combination with Ipilimumab • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 3: Nivolumab monotherapy or combination with Ipilimumab 0 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) 0 • Any other systemic anti-cancer therapy <5 Palliative care only unable to answer | |
| Question Number 4: In the past 3 months, how many patients have been initiated* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer: • Nivolumab monotherapy or in combination with Ipilimumab • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. | |
| Answer To Question 4: • Nivolumab monotherapy or in combination with Ipilimumab <5 • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0 *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. | |
| Question Number 5: Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 5: The Trust is not currently participating in any clinical trials for gastric cancer. | |
| Question Number 6: Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 6: The Trust is not currently participating in any clinical trials for oesophageal cancer. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
